Journal
ONCOTARGET
Volume 7, Issue 25, Pages 37714-37727Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.9265
Keywords
CCR4; Treg; antitumor immunity; prognosis; head and neck squamous cell carcinoma
Categories
Funding
- National Natural Science Foundation of China [81271055, 81470674]
- Doctoral Foundation of Ministry of Education of China [20120171110049]
- Science and Technology Planning Project of Guangdong Province [2014A020212141]
Ask authors/readers for more resources
FoxP3(+) regulatory T (Treg) cells have diverse functions in the suppression of antitumor immunity. We show that FoxP3(hi)CD45RA(-)CD4(+) Treg cells [activated Treg (aTreg) cells] are the predominant cell population among tumor-infiltrating FoxP3(+) T cells, and that high aTreg cell-infiltrating content is associated with reduced survival in patients with head and neck squamous cell carcinoma (HNSCC). In vitro studies have demonstrated that aTreg cells can suppress tumor-associated antigen (TAA) effector T cell immune responses in HNSCC. Moreover, C-C chemokine receptor 4 (CCR4) was specifically expressed by aTreg cells in the peripheral blood of HNSCC patients. Using a RayBiotech human chemokine antibody array, we showed that monocyte chemoattractant protein-1 (MCP-1), an endogenous CCR4-binding ligand, was specifically upregulated in the HNSCC microenvironment compared to the other four CCR4-binding ligands. Blocking MCP-1/CCR4 signaling-induced aTreg cell recruitment using a CCR4 antagonist evoked antitumor immunity in mice, and lead to inhibition of tumor growth and prolonged survival. Therefore, blocking aTreg cell trafficking in tumors using CCR4-binding agents may be an effective immunotherapy for HNSCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available